RRBS methylation status assessment is a cost-effective, high-resolution technique for profiling DNA methylation across CpG-rich genomic regions using reduced representation bisulfite sequencing. This approach enriches promoter regions and CpG islands while sequencing only a small fraction of the genome, dramatically reducing costs while delivering single-base resolution methylation data. Our comprehensive RRBS services provide researchers with reliable methylation profiling for epigenetic studies in cancer research, developmental biology, and biomarker discovery.
Technical Overview
Reduced Representation Bisulfite Sequencing (RRBS) is a powerful and widely adopted method for DNA methylation profiling that combines enzymatic digestion, DNA fragmentation, and bisulfite conversion with next-generation sequencing (NGS). The technique leverages the methylation-insensitive restriction enzyme MspI, which cleaves DNA at CCGG recognition sites regardless of cytosine methylation status, generating fragments enriched in CpG-rich regions such as CpG islands, promoters, and enhancers.
By selectively sequencing approximately 1–5% of the genome, RRBS achieves a remarkable balance between coverage depth and sequencing cost, making large-scale comparative methylation studies economically feasible. Following bisulfite conversion, unmethylated cytosines are deaminated to uracils while methylated cytosines remain unchanged, enabling single-nucleotide resolution quantification of methylation levels at individual CpG dinucleotides. RRBS methylation status assessment is particularly well suited for studies requiring precise methylation quantification at regulatory regions across multiple samples, including clinical cohorts.
Compared with whole-genome bisulfite sequencing (WGBS), RRBS requires substantially less input DNA (as low as 10–300 ng) and delivers higher sequencing depth per CpG, which improves statistical confidence in methylation estimates at covered loci. These characteristics make RRBS an ideal choice for researchers investigating promoter methylation, CpG island biology, and differentially methylated regions (DMRs) in disease and development.
Testing Samples
Tissue Samples
Fresh frozen tissues, ethanol-preserved tissues, and laser-capture microdissected specimens are accepted. A minimum of 20 mg of tissue is recommended to ensure sufficient high-quality genomic DNA extraction. Tissue samples should be transported on dry ice to prevent DNA degradation.
Blood and Body Fluid Samples
Peripheral blood collected in EDTA anticoagulant tubes, buffy coat fractions, plasma, and other biological fluids are suitable for RRBS analysis. A minimum volume of 200 µL (or approximately 1–2 mL for cell-free DNA applications) is typically required. Samples should be stored at −80°C prior to shipment.
Cell Samples
Cultured cell pellets, sorted cell populations, and single-cell-derived clones can be analyzed. A minimum of 1 × 10⁵ to 1 × 10⁶ cells is recommended depending on genome coverage requirements. Cells should be pelleted, flash-frozen, and shipped frozen.
FFPE Samples
Formalin-fixed paraffin-embedded (FFPE) tissue sections and scrolls are acceptable provided that DNA quality is verified. Because FFPE-derived DNA is often fragmented, additional quality control steps and optimized library preparation protocols are applied to ensure reliable methylation calls.
Extracted Genomic DNA
Directly submitted genomic DNA is welcome provided it meets quality standards: concentration ≥ 20 ng/µL, total amount ≥ 100 ng, OD260/280 ratio between 1.8 and 2.0, and minimal degradation confirmed by agarose gel electrophoresis or TapeStation/Fragment Analyzer assessment.
Testing Items
Our RRBS methylation status assessment service delivers a comprehensive panel of analytical outputs:
- Global methylation profiling at single-base resolution across CpG islands, shores, shelves, promoters, 5′UTR, 3′UTR, exons, introns, and intergenic regions
- Quantitative methylation levels (beta values) at individual CpG sites with coverage-based filtering
- Identification and annotation of differentially methylated regions (DMRs) and differentially methylated CpG sites (DMCs) between comparison groups
- Methylation distribution analysis across gene bodies and regulatory elements
- Chromosome-level methylation landscape visualization
- Correlation analysis between DNA methylation and gene expression (when RNA-seq data are provided)
- Functional enrichment analysis of DMR-associated genes, including GO and KEGG pathway analysis
- Comprehensive quality control metrics, including bisulfite conversion rate, library complexity, and sequencing duplication rates
Testing Methods
The RRBS workflow integrates optimized molecular biology procedures with rigorous bioinformatics analysis:
- Sample QC and DNA extraction: Genomic DNA is extracted using column-based or magnetic bead-based methods and quantified by Qubit fluorometry. DNA integrity is evaluated via agarose gel electrophoresis or automated electrophoresis systems.
- Restriction digestion: High-quality genomic DNA (100–300 ng) is digested with the methylation-insensitive enzyme MspI, which enriches fragments flanking CCGG sites in CpG-dense regions.
- End repair and adenylation: Fragment ends are polished and 3′-dA overhangs are added to facilitate directional adapter ligation.
- Methylated adapter ligation: Fully methylated sequencing adapters are ligated to digested fragments, ensuring that adapter cytosines are protected from bisulfite conversion.
- Size selection: DNA fragments of 150–350 bp (including adapter sequences) are selected using bead-based purification to enrich for CpG-dense genomic windows.
- Bisulfite conversion: Size-selected libraries undergo bisulfite treatment, converting unmethylated cytosines to uracil while preserving methylated cytosines (conversion efficiency typically exceeds 99%).
- PCR amplification: Converted libraries are amplified using high-fidelity uracil-tolerant polymerases with minimal cycle numbers to reduce amplification bias.
- Sequencing: Libraries are sequenced on the Illumina NovaSeq or MGISEQ platforms, with paired-end 150 bp reads recommended. Typical data output ranges from 5–10 million reads per sample.
- Bioinformatics analysis: Reads undergo quality trimming, adapter removal, and alignment to the reference genome using specialized bisulfite-aware aligners (Bismark or BS-Seeker2). Methylation calling is performed at each covered CpG site, followed by DMR detection, annotation, and integrative downstream analyses.
Applications
RRBS methylation status assessment supports a broad spectrum of research applications:
- Cancer epigenetics: Identification of aberrant promoter hypermethylation of tumor suppressor genes and global hypomethylation patterns across cancer types, contributing to understanding of oncogenic mechanisms and epigenetic subtyping of tumors.
- Biomarker discovery: Development of methylation-based diagnostic, prognostic, and predictive biomarkers for early cancer detection, treatment response monitoring, and minimal residual disease assessment.
- Developmental biology: Characterization of methylation reprogramming events during embryogenesis, gametogenesis, and cellular differentiation.
- Environmental epigenomics: Investigation of methylation changes induced by environmental exposures, diet, toxins, and stress.
- Aging research: Analysis of epigenetic clocks and age-associated methylation drift at CpG-dense loci.
- Plant and agricultural genomics: Methylation profiling in plant species with complex genomes, where symmetrical CHG and CHH contexts can also be assessed using modified RRBS protocols.
- Drug development: Evaluation of DNA methyltransferase inhibitors (such as decitabine and azacitidine) and other epigenetic therapeutics in preclinical and clinical studies.
- Comparative epigenomics: Cross-species and cross-tissue comparisons of methylation patterns at conserved regulatory regions.
FAQ
What is the minimum DNA input required for RRBS?
Standard RRBS protocols require 100–300 ng of high-quality genomic DNA. Low-input protocols optimized for as little as 10 ng can be provided for precious samples such as microdissected specimens, although additional replicates may be recommended to ensure data reliability.
What genome coverage can I expect from RRBS?
RRBS typically captures 5–10% of all CpG sites in the genome, with strong enrichment at CpG islands, promoters, and other regulatory regions. At a sequencing depth of 5–10 million reads per sample, approximately 1–2 million CpG sites can be quantified with high confidence.
How does RRBS compare with WGBS and methylation arrays?
WGBS provides genome-wide CpG coverage but at significantly higher cost and input DNA requirements. Methylation arrays (such as the Illumina Infinium MethylationEPIC array) offer fixed CpG content and cannot interrogate non-mammalian species or novel loci. RRBS occupies an intermediate position, providing flexible, sequencing-based methylation profiling at regulatory regions with substantially lower cost than WGBS and greater flexibility than arrays.
Can RRBS detect non-CpG methylation?
Yes, methylation at CHG and CHH contexts can be quantified when appropriate bioinformatics parameters are applied. This is particularly relevant for plant epigenomics studies, where non-CpG methylation is biologically significant.
Can FFPE samples be analyzed using RRBS?
Yes, FFPE samples are compatible with RRBS following DNA quality assessment. Because bisulfite conversion itself fragments DNA, the additional fragmentation present in FFPE-derived DNA has relatively limited impact on RRBS library construction compared with other NGS applications.
How many biological replicates are recommended?
A minimum of three biological replicates per group is recommended for robust statistical analysis of differential methylation. For clinical cohort studies, sample sizes of 10–20 or more per group enhance statistical power for detecting subtle methylation differences.
What reference genomes are supported?
We support all reference genomes with high-quality assemblies and gene annotations, including human (hg38, hg19), mouse (mm10, mm39), rat, zebrafish, and numerous plant species. Custom reference genomes can be accommodated upon request.
How long does the RRBS service take?
Standard turnaround time is 30–45 business days from sample receipt to delivery of the full analysis report, depending on sample number, sequencing queue, and the complexity of downstream bioinformatics analysis.